Systematic Review and Network Meta-Analysis on Treating Hormone Receptor-Positive Metastatic Breast Cancer After CDK4/6 Inhibitors

Systematic Review and Network Meta-Analysis on Treating Hormone Receptor-Positive Metastatic Breast Cancer After CDK4/6 Inhibitors

Introduction: The optimal treatment of estrogen receptor-positive (ER +) metastatic breast cancer (MBC) after progression on cyclin-dependent 4/6 kinase inhibitors (CDK4/6i) is unknown. Methods: We conducted a systematic review and network meta-analysis (NMA) of phase-II/-III randomized trials of ER...

Full description

Saved in:

Bibliographic Details
Main Authors:	Neha Pathak, Abhenil Mittal, Sudhir Kumar, Chitrakshi Nagpal, Eitan Amir, Partha Haldar, Bharath B. Gangadharaiah, Akash Kumar, Ashutosh Mishra, Atul Batra
Format:	Article
Language:	English
Published:	MDPI AG 2025-01-01
Series:	Current Oncology
Subjects:	metastatic breast cancer CDK4/6 inhibitor hormone receptor-positive cancer SERD HER2-low breast cancer AKT inhibitor
Online Access:	https://www.mdpi.com/1718-7729/32/1/53
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): Mechanisms of resistance and where to find them
by: L. Foffano, et al.
Published: (2025-02-01)

Evaluating the Effectiveness of Cyclin-Dependent Kinase 4/6 Inhibitors in Early- and Very Early-Onset Metastatic Breast Cancer: A Multicenter Study
by: Akif Doğan, et al.
Published: (2025-01-01)

Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer
by: Paola Zagami, et al.
Published: (2025-02-01)

Dual Inhibition of CDK4/6 and CDK7 Suppresses Triple‐Negative Breast Cancer Progression via Epigenetic Modulation of SREBP1‐Regulated Cholesterol Metabolism
by: Yilan Yang, et al.
Published: (2025-02-01)

Real-World Experience with CDK4/6 Inhibitors in the First-Line Palliative Setting for HR+/HER2− Advanced Breast Cancer
by: Ram Patel, et al.
Published: (2025-01-01)

Safety of Abemaciclib in Indian Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced and/or Metastatic Breast Cancer: A Multicenter, Nonrandomized, Open-Label, Single-Arm, Phase 4 Study
by: Dinesh Chandra Doval, et al.

RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast cancer
by: Charlotte K. Kindt, et al.
Published: (2025-01-01)

Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13])
by: A. DeMichele, et al.
Published: (2025-01-01)

Exploring adherence in patients with advanced breast cancer: focus on CDK4/6 inhibitors
by: Baković Matea, et al.
Published: (2023-12-01)

Strategies for preventing and managing osteoporosis in elderly breast cancer patients undergoing aromatase inhibitor therapy
by: Andi Tian, et al.
Published: (2025-01-01)

CARDIAC-STAR: prevalence of cardiovascular comorbidities in patients with HR + /HER2 − metastatic breast cancer
by: Susan Dent, et al.
Published: (2025-01-01)

Advanced breast cancer with pancreatic metastasis responding well to TKIs after ADC failure: Report of a rare case
by: Huiyun Lv, et al.
Published: (2025-02-01)

Monitoring and management of adverse effects associated with trastuzumab deruxtecan: a UAE-specific consensus
by: Emad Dawoud, et al.
Published: (2025-01-01)

Stroke associated with microvascular tumoral infiltration in a patient with metastatic breast cancer
by: Joshua Mangerel, MD, et al.
Published: (2025-03-01)

Multitarget CDK inhibitors roscovitine and UCN‑01 induce apoptosis in colorectal cancer cells by inhibiting cell cycle progression and transcription
by: Sonal Mohan Manohar, et al.
Published: (2025-01-01)

Potential antiproliferative effect of isoxazolo- and thiazolo coumarin derivatives on breast cancer mediated bone and lung metastases
by: Ballazhi Lulzime, et al.
Published: (2015-03-01)

Trifluridine-tipiracil in previously treated patients with oestrogen receptor-positive, HER2-negative metastatic breast cancer (BOOG 2019-01 TIBET trial): a single-arm, multicentre, phase 2 trialResearch in context
by: Niels A.D. Guchelaar, et al.
Published: (2025-02-01)

Computational studies and structural insights for discovery of potential natural aromatase modulators for hormone-dependent breast cancer
by: Snehal Aditya Arvindekar, et al.
Published: (2024-09-01)

Proton pump inhibitors enhance chemosensitivity, promote apoptosis, and suppress migration of breast cancer cells
by: Ihraiz Worood G., et al.
Published: (2020-06-01)

Impacts of genomic alterations on the efficacy of HER2-targeted antibody–drug conjugates in patients with metastatic breast cancer
by: Riqing Huang, et al.
Published: (2025-01-01)

Review of the clinical status of cardiotoxicity of HER-2 positive breast cancer targeted therapeutic drugs
by: Xiang Zhang, et al.
Published: (2025-02-01)

Evaluating the impact of a tertiary multidisciplinary meeting in metastatic breast cancer: A prospective study
by: Belinda Sassé, et al.
Published: (2025-02-01)

Case report: Unraveling a unique case of male occult breast cancer with axillary intricacies and a comprehensive literature dive
by: Xintong Xie, et al.
Published: (2025-02-01)

A patient-led survey on information and communication needs of patients with metastatic breast cancer in Ireland and Northern Ireland (CTRIAL-IE 23–05)
by: Siobhan Gaynor, et al.
Published: (2025-02-01)

The impact on productivity costs of reducing unemployment in patients with advanced breast cancer: A model estimation based on a Portuguese nationwide observational study
by: Leonor Vasconcelos de Matos, et al.
Published: (2025-02-01)

Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma
by: Laura Scalambra, et al.
Published: (2025-01-01)

Medication patterns and potentially inappropriate medication in patients with metastatic breast cancer: results of the BRE-BY-MED study
by: Lilly Sophia Brandstetter, et al.
Published: (2025-01-01)

Nomograms for predicting recurrence of HER2‐positive breast cancer with different HR status based on ultrasound and clinicopathological characteristics
by: Xudong Zhang, et al.
Published: (2024-09-01)

Blood-based prognostic scores and early dynamics under immunotherapy to select patients with metastatic solid tumors for continuing immune check-point inhibition: a prospective longitudinal study
by: Javier García-Corbacho, et al.
Published: (2025-02-01)

Investigation of survival and prognostic factors in triple negative molecular subtype male breast cancer patients: A population-based study
by: Ahmet Necati Sanli, et al.
Published: (2024-04-01)

Ribociclib-induced vitiligo in a case of metastatic carcinoma of the breast
by: Abhira Deb, et al.
Published: (2025-01-01)

Case report: Near-complete response to neratinib-based treatment in HR-positive HER2-amplified metastatic breast cancer refractory to trastuzumab deruxtecan
by: Ünal Metin Tokat, et al.
Published: (2025-01-01)

Very first real-world data on zongertinib use in non-small cell lung cancer patients with HER2 mutations: A brief report
by: Oliver Illini, et al.
Published: (2024-01-01)

Influence of ethnicity on cyclin-dependent kinase inhibitor efficacy and toxicity: A systematic review and meta-analysis
by: Roberto Buonaiuto, et al.
Published: (2025-02-01)

A multicenter retrospective study of early cardiac toxicity in operable breast cancer patients receiving concurrent dual or mono anti-HER2 therapy with postoperative radiation therapy
by: Jing Yang, et al.
Published: (2025-02-01)

PhyIndBC: Development of a machine learning tool for screening of potential breast cancer inhibitors from phytochemicalsGitHub
by: Agneesh Pratim Das, et al.
Published: (2025-06-01)

Harnessing artificial intelligence for predicting breast cancer recurrence: a systematic review of clinical and imaging data
by: Jaqueline Alvarenga Silveira, et al.
Published: (2025-02-01)

Immunotherapy in metastatic renal cell carcinoma: Insights from a Dutch nationwide cohort
by: Hilin Yildirim, et al.
Published: (2025-02-01)

Motivations and perceptions for physical activity in women living with metastatic breast cancer: a qualitative interview study
by: Mark Liu, et al.
Published: (2025-01-01)

PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2− breast cancer
by: Eduardo Terán, et al.
Published: (2024-09-01)